Chronic Kidney Disease Market Research Report: By Diagnosis (Blood Test, Urine Test, Biopsy), by Treatment (Drugs, Dialysis, Kidney Transplant), by Indication (Type 1 or Type 2 Diabetes, High Blood Pressure), End-User (Hospitals) – Global Forecast Till 2023
Chronic Kidney Disease Market is a medical condition where the level of waste products, and other fluids levels are increased in the human body due to loss of kidney function, especially in the advanced stage of the disease. Market Research Future (MRFR) has launched a comprehensive report on the global chronic kidney disease market, where forecasts for the period of 2017-2023 is provided with key dynamics that can impact the market growth in the coming years. AS per MRFR’s analysis, the market is poised to post a CAGR of 5.2% over the forecast period.
Rise in the incidence rate of diabetes is a crucial factor driving the growth of the chronic kidney disease market. The disease is predicted to affect close to 10% of the global population and characterized by kidney damage. People with diabetes are at higher risk of acquiring the disease. Cardiovascular disorders also raise the chance of the incidence of the disease. In recent years, growing availability and development of advanced treatment and diagnosis techniques have facilitated early diagnosis of the disease. Government initiatives aimed at minimizing the symptoms and complications of the disease through funding for R&D activities.
The chronic kidney disease market has been segmented based on diagnosis, treatment, indication, and end-user.
By diagnosis, the chronic kidney disease market has been segmented into blood test, urine test, imaging test, and kidney biopsy.
By treatment, the chronic kidney disease market has been segmented into drugs, dialysis, and kidney transplant. The drugs segment has been further segmented into ace inhibitors, angiotensin-ii receptor blockers, calcium channel blockers, beta-blockers, and erythropoiesis-stimulating agents.
By indication, the chronic kidney disease market has been segmented into Type 1 or Type 2 diabetes, high blood pressure, polycystic kidney disease, and others.
By end-user, the chronic kidney disease market has been segmented into hospitals and clinics, diagnostic centers, and others.
Browse Complete Report :https://www.marketresearchfuture.com/reports/chronic-kidney-disease-market-5744
Region-wise, teh chronic kidney diseases market has been segmented into the Americas, Europe, the Middle East & Africa (MEA), and Asia Pacific (APAC).
The Americas has attained the foremost position in the global chronic kidney diseases market. The growth of the market can be attributed to the surging prevalence of kidney-related disorders in the region, availability of advanced imaging and diagnostic procedures, and technological developments brought about extensive R&D activities. High healthcare expenditure and favorable reimbursement scenario also supports the growth of the market.
The Europe market accounts for a substantial share of the global market and is driven by increasing occurrence and awareness about risk factors of kidney disorders in the region. Elevating government support and heightened focus on the development of new therapies and drugs also underpin the growth of the market.
APAC is poised to be the fastest growing chronic kidney diseases market. The rise in the incidence of risk factors such as diabetes and other lifestyle related diseases in the region is fueling the growth of the market. Expanding healthcare infrastructure, growing availability of advanced treatment options, and investment in healthcare technology by the private and public sector is favoring the growth of the market.
Limited awareness regarding kidney disorders and lack of access to advanced treatment and other medical facilities is restricting the growth of the MEA market.
Pfizer Inc., Siemens, URIT Medical, F. Hoffmann-La Roche Ltd., Amgen Inc., Beckman Coulter, and Kissei Pharmaceutical Co. Ltd., F. Hoffmann-La Roche Ltd., OPTI Medical, Teva Pharmaceutical Industries Ltd., Sysmex, Randox Laboratories, ARKRAY, Nova Biomedical, AstraZeneca Plc, ACON Laboratories, Inc., Sanofi S.A., 77 Elektronika, GlaxoSmithKline Plc, Abbott, and AbbVie Inc.